Durvalumab-induced Lesions of Bronchiolitis and Fully Reversible Bronchiectasis in a Patient with Non-small Cell Lung Cancer: A Case Report

Overview

Journal Thorac Cancer

Specialties Oncology
Pulmonary Medicine

Date 2021 Feb 24

PMID 33624409

Citations 3

Authors

Mael Domblides

Margaux Geier

Chantal Decroisette

Renaud Descourt

Affiliations

Soon will be listed here.

Abstract

Durvalumab is a humanized monoclonal antibody targeting programmed cell death ligand-1 (PD-L1), leading to an antitumor activity, used as consolidation therapy in patients with locally advanced unresectable non-small cell lung cancer (NSCLC). Several immune-related adverse events (irAEs) have previously been described in patients following treatment with immune checkpoint inhibitors (ICIs). To the best of our knowledge, we report the first case of immunotherapy-induced fully reversible bronchiolitis and bronchiectasis, despite the fact that its pathophysiological mechanism has been previously considered to be irreversible.

Citing Articles

Sarcoidosis and Airway Disease After Immune Checkpoint Inhibitor Therapy: Case Study and Review of the Literature.

Soto F, Torre-Sada L, Mott F, Kim S, Nurieva R, Shannon V J Immunother Precis Oncol. 2023; 6(2):111-116.

PMID: 37214206 PMC: 10195014. DOI: 10.36401/JIPO-22-30.

A case of eosinophilic bronchiolitis after the initiation of immune checkpoint inhibitor.

Tamura A, Hashimoto M, Hosoi A, Hojo M Thorac Cancer. 2023; 14(19):1894-1898.

PMID: 37201911 PMC: 10317597. DOI: 10.1111/1759-7714.14931.

Durvalumab-induced lesions of bronchiolitis and fully reversible bronchiectasis in a patient with non-small cell lung cancer: A case report.

Domblides M, Geier M, Decroisette C, Descourt R Thorac Cancer. 2021; 12(8):1240-1243.

PMID: 33624409 PMC: 8046106. DOI: 10.1111/1759-7714.13862.

References

Delaunay M, Prevot G, Collot S, Guilleminault L, Didier A, Mazieres J . Management of pulmonary toxicity associated with immune checkpoint inhibitors. Eur Respir Rev. 2019; 28(154). PMC: 9488507. DOI: 10.1183/16000617.0012-2019. View

Antonia S, Villegas A, Daniel D, Vicente D, Murakami S, Hui R . Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. N Engl J Med. 2017; 377(20):1919-1929. DOI: 10.1056/NEJMoa1709937. View

Yamasaki M, Taniwaki M, Kawamoto K, Matsumoto N, Hashimoto K, Nabeshima S . Durvalumab-induced Organizing Pneumonia with a Diffuse Micronodular Pattern in a Patient with Lung Cancer. Am J Respir Crit Care Med. 2019; 201(8):e52-e53. DOI: 10.1164/rccm.201907-1310IM. View

Maeno K, Fukuda S, Oguri T, Niimi A . Nivolumab-induced asthma in a patient with non-small-cell lung cancer. Ann Oncol. 2017; 28(11):2891. DOI: 10.1093/annonc/mdx455. View

Polverino E, Goeminne P, McDonnell M, Aliberti S, Marshall S, Loebinger M . European Respiratory Society guidelines for the management of adult bronchiectasis. Eur Respir J. 2017; 50(3). DOI: 10.1183/13993003.00629-2017. View

Domblides M, Geier M, Decroisette C, Descourt R . Durvalumab-induced lesions of bronchiolitis and fully reversible bronchiectasis in a patient with non-small cell lung cancer: A case report. Thorac Cancer. 2021; 12(8):1240-1243. PMC: 8046106. DOI: 10.1111/1759-7714.13862. View

Yap V, Metersky M . Reversible bronchiectasis in an adult: a case report. J Bronchology Interv Pulmonol. 2012; 19(4):336-7. DOI: 10.1097/LBR.0b013e31826ca79d. View

Nishino M, Sholl L, Hodi F, Hatabu H, Ramaiya N . Anti-PD-1-Related Pneumonitis during Cancer Immunotherapy. N Engl J Med. 2015; 373(3):288-90. PMC: 4539956. DOI: 10.1056/NEJMc1505197. View

Kucuk C, Turkkani M, Arda K . A case report of reversible bronchiectasis in an adult: Pseudobronchiectasis. Respir Med Case Rep. 2019; 26:315-316. PMC: 6409408. DOI: 10.1016/j.rmcr.2019.03.002. View

10.

Chalmers J, Hill A . Mechanisms of immune dysfunction and bacterial persistence in non-cystic fibrosis bronchiectasis. Mol Immunol. 2012; 55(1):27-34. DOI: 10.1016/j.molimm.2012.09.011. View

11.

McAlees J, Lajoie S, Dienger K, Sproles A, Richgels P, Yang Y . Differential control of CD4(+) T-cell subsets by the PD-1/PD-L1 axis in a mouse model of allergic asthma. Eur J Immunol. 2015; 45(4):1019-29. PMC: 4440042. DOI: 10.1002/eji.201444778. View

12.

King P . The Role of the Immune Response in the Pathogenesis of Bronchiectasis. Biomed Res Int. 2018; 2018:6802637. PMC: 5878907. DOI: 10.1155/2018/6802637. View

13.

Naidoo J, Wang X, Woo K, Iyriboz T, Halpenny D, Cunningham J . Pneumonitis in Patients Treated With Anti-Programmed Death-1/Programmed Death Ligand 1 Therapy. J Clin Oncol. 2016; 35(7):709-717. PMC: 5559901. DOI: 10.1200/JCO.2016.68.2005. View

14.

Haanen J, Carbonnel F, Robert C, Kerr K, Peters S, Larkin J . Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017; 28(suppl_4):iv119-iv142. DOI: 10.1093/annonc/mdx225. View

15.

Keicho N, Hijikata M . Genetic predisposition to diffuse panbronchiolitis. Respirology. 2011; 16(4):581-8. DOI: 10.1111/j.1440-1843.2011.01946.x. View

16.

Ogawa T, Miyata J, Maehara J, Inoue T, Betsuyaku T . Fatal Airway Inflammation Induced by Pembrolizumab in a Patient With NSCLC. J Thorac Oncol. 2018; 14(1):e9-e10. DOI: 10.1016/j.jtho.2018.09.002. View

17.

Zubiri L, Allen I, Taylor M, Guidon A, Chen S, Schoenfeld S . Immune-Related Adverse Events in the Setting of PD-1/L1 Inhibitor Combination Therapy. Oncologist. 2020; 25(3):e398-e404. PMC: 7066708. DOI: 10.1634/theoncologist.2018-0883. View

18.

Anderson R, Theron A, Rapoport B . Immunopathogenesis of Immune Checkpoint Inhibitor-Related Adverse Events: Roles of the Intestinal Microbiome and Th17 Cells. Front Immunol. 2019; 10:2254. PMC: 6775220. DOI: 10.3389/fimmu.2019.02254. View